My Alcon | United States

This page is available in English. Select below for other locations.

Unlock First-Line Glaucoma Care with Voyager™ DSLT

Voyager™ DSLT is designed to automatically deliver 120 laser pulses directly through the limbus to the trabecular meshwork to improve aqueous outflow and reduce intraocular pressure.

GET IN TOUCH

Introducing Voyager™ DSLT

Evolving first-line treatment paradigm

Effective IOP lowering with a proven safety profile

Simplified workflow for an efficient practice

Exceptional experience for the patient and physician

Three images showcasing the Alcon Voyager DSLT glaucoma treatment laser system. The first image highlights the device's ergonomic design and comfortable gonio-free experience. The second image shows the intuitive touch screen interface with automatic target definition. The third image focuses on the precision delivery mechanism of the device."

Evolving First-Line Treatment Paradigm

The Laser in Glaucoma and Ocular Hypertension (LiGHT) study found that SLT is efficacious as a primary procedure for the treatment of OAG and OHT.¹

Recognizes SLT as an effective primary intervention for OAG²

Recommends that SLT should be considered as an initial treatment option for mild or moderate OAG and OHT patients³

Recommends 360^o SLT as first-line treatment for people with newly diagnosed OHT and COAG⁴

DOWNLOAD FACTSHEET

Exceptional Experience for the Patient and Physician

Effective IOP-Lowering with a Proven Safety Profile

Direct Selective Laser Trabeculoplasty (DSLT) in Open Angle Glaucoma (OAG) and Ocular Hypertension (OHT): A Randomized Controlled Trial (GLAUrious)⁵

6 MONTHS

12 MONTHS

Decreased Medication Burden

At 12 months⁵:

of all DSLT patients were medication-free

of DSLT patients who entered the study medication-free, remained medication-free

of DSLT patients were on the same or fewer medications

Proven Safety Profile with Low Rate of Adverse Events

In DSLT group⁵:

No ocular serious AEs as a result of the procedure through 12 months

Extremely low rate of SSIs* for IOP control at 12 months

*Secondary Surgical Interventions

Low rate of non-serious AEs at >6 months

Voyager™ DSLT Resources

2022 Journal of
Glaucoma

Energy Dose-Response in Selective Laser Trabeculoplasty: A Review

Radcliffe N, et al.

Read More

2021 TVST – ARVO
Journal

Automated Direct Selective Laser Trabeculoplasty: First Prospective Clinical Trial

Goldenfeld M, et al.

Read More

2021 British Journal of
Ophthalmology

Direct selective laser trabeculoplasty in open angle glaucoma study design

Congdon N, et al.

Read More

GET IN TOUCH DOWNLOAD BROCHURE

References:

1. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2023;130(2):139-151.

2. Takusagawa HL, Hoguet A, Sit AJ, et al. Selective laser trabeculoplasty for the treatment of glaucoma. Ophthalmology. 2024;131(1):37-47. doi:10.1016/j.ophtha.2023.07.029.

3. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105(Suppl 1):1-169. doi:10.1136/bjophthalmol-2021-egsguidelines.

4. National Institute for Health and Care Excellence. Glaucoma: Diagnosis and Management. London: National Institute for Health and Care Excellence (NICE); 2022.

5. GLAUrious Study - Clinical Study Report (CSR). CA-RP-01-006, Rev. 01; 2022.

Important safety information

Alcon Voyager™ DSLT Important Product Information

Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician. Intended Use: Voyager™ DSLT is a prescription device intended for use in performing selective laser trabeculoplasty.

Indications: Voyager™ DSLT is indicated for use in selective laser trabeculoplasty (SLT).

Contraindications: Use of the Voyager™ DSLT device is contraindicated in the following patients:

Patients who are unable to fixate their head and/or eyes, such as patients suffering from uncontrolled nystagmus, tremors or similar conditions.

Patients with a pupil that cannot constrict to a diameter of 4 mm or less.

Warnings:

Users should wear laser safety eyewear while performing a procedure with the Voyager DSLT device to avoid injury to the user’s eyes.

Use of controls or adjustments or performance of procedures other than those specified herein may result in hazardous laser radiation exposure.

Caution should be used when treating patients who have active uveitis or neovascularization that involves the iridocorneal angle with the Voyager DSLT device.

The effect of selective laser trabeculoplasty energy on glaucoma implants located in the iridocorneal angle has not been studied. Because your version of the Voyager DSLT device does not allow masking of the implant area (i.e. ability to program a laser pattern which skips the local area of the implant), the use of the device is not recommended in eyes which have a glaucoma implant at any clock hour in the iridocorneal angle.

In the pivotal clinical study of the Voyager DSLT device, the safety and effectiveness of re-treatment was not studied; therefore, the level of IOP reduction and potential for complications associated with re-treatment has not been established. Re-treatment is not recommended.

ATTENTION: Refer to the Voyager™ DSLT Directions for Use operating instructions and for the accessories/consumables and User Guide for a complete listing of indications, warnings, cautions and notes.